Compare NVAX & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | AMPH |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1995 | 2014 |
| Metric | NVAX | AMPH |
|---|---|---|
| Price | $7.16 | $26.40 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $9.75 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 3.2M | 363.2K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.07 | ★ 2.27 |
| Revenue | ★ $1,064,651,000.00 | $723,305,000.00 |
| Revenue This Year | $58.91 | $1.35 |
| Revenue Next Year | N/A | $5.10 |
| P/E Ratio | ★ $3.25 | $11.81 |
| Revenue Growth | ★ 20.27 | N/A |
| 52 Week Low | $5.01 | $20.39 |
| 52 Week High | $11.55 | $39.01 |
| Indicator | NVAX | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 58.83 | 49.11 |
| Support Level | $6.60 | $26.26 |
| Resistance Level | $7.00 | $27.23 |
| Average True Range (ATR) | 0.21 | 0.77 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 98.20 | 52.68 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.